 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19827 News |  |
| «12...166167168169170171172173174175176...203204» |
- CLINICAL EFFECTIVENESS OF FIRST-LINE ANTI-TNF THERAPIES AND SECOND-LINE ANTI-TNF THERAPY POST-VEDOLIZUMAB DISCONTINUATION IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2490;
This suggests that 1L VDZ may not impact the effectiveness of subsequent anti-TNF Tx in real-world clinical practice. As 2L sample size was limited, these hypothesis-generating data warrant further study.
- PSORIASIS UNDER TNF-A INHIBITORS IN INFLAMMATORY BOWEL DISEASE PATIENTS: A 19-YEAR EXPERIENCE OF A TERTIARY CENTRE (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2489;
The majority of our patients improved their skin condition with anti-TNF switch, despite lack of studies regarding this. The incidence of this lesions on IBD patients treated anti-TNF therapy(6-11%) is consistent with that found in other diseases like rheumatoid arthritis.
- Humira (adalimumab) / Eisai, AbbVie
THE REAL WORLD USE OF FECAL CALPROTECTIN HOME TESTING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDER MAINTENANCE TREATMENT WITH ADALIMUMAB (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2473;
The IBD patients' compliance rate of performing the FC home test is high (87.5%). Moreover, our results confirm the important role of consecutive FC measurements at home, in combination with the endoscopic evaluation for the optimization of treatment in IBD patients receiving maintenance treatment with adalimumab.
- Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
INCIDENTAL DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE FROM THE ENGLISH BOWEL CANCER SCREENING PROGRAMME -FOLLOW UP OF THE FIRST REPORTED COHORT (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2469;
With the advent of endoscopic bowel cancer screening this number is set to increase. Incidental IBD appears to follow an indolent course over age 60 with a stable disease phenotype This subset of patients may present an important model for study of early disease providing novel insights into disease pathogenesis and evolving treatment paradigms.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
LONG-TERM HEALTH STATE OF CHILDREN BORN FROM IBD MOTHERS EXPOSED TO ANTI-TNF TREATMENT DURING PREGNANCY (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2462;
Introduction: Infliximab (IFX), adalimumab (ADL) and golimumab (GLM) are anti-TNF inhibitors of IgG1 class which do not cross the placenta until the 3nd trimester of the pregnancy; therefore, they are considered a safe treatment for the foetus during the 1st and 2nd trimester of the pregnancy. In this small, single-centre, prospective study, treatment with IgG1-anti-TNF agents until the 26th gestational week does not seem to be related with later development, response to vaccinations, or any later adverse life events.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
OUTCOME OF IMMEDIATE INFLIXIMAB OPTIMISATION BASED ON RAPID ASSESSMENT OF SERUM DRUG AND FECAL CALPROTECTIN CONCENTRATIONS IN INFLAMMATORY BOWEL DISEASES PATIENTS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2449;
Our results suggest benefit of using rapid tests in daily practice. Results of rapid, lateral flow-based assays and ELISA kits are correlated.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
FUNCTIONAL RARE VARIANTS INFLUENCE THE CLINICAL RESPONSE TO ANTI-TNF THERAPY IN CROHN'S DISEASE (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2440;
Cell-type enrichment analysis suggests that the gut mucosa and CD8+ T cells are the main mediators of this response. These findings provide new insights into the underlying heterogeneity of CD, revealing the basis of TNF-dependent biological mechanisms
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
PRESENCE OF ANXIETY AND DEPRESSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN ALBANIA (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2409;
A significant number of patients with IBD, suffer from depression and/or anxiety and this has an important impact on their quality of life. Patients with a severe disease activity are at a higher risk for anxiety and depression and this may suggest that it can be important to start screeningall the IBD patients with this questionnaire in order to evaluate them and eventually refer them to the psychiatrists.
- EFFICACY AND SAFETY OF ANTI-TNFα THERAPY IN BUDESONIDE REFRACTORY, DEPENDENT OR INTOLERANT MICROSCOPIC COLITIS: A FRENCH REGISTRY (Barcelona) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2086;
To date, this is the biggest case series evaluating the efficacy and safety of anti-TNFα in refractory MC. Anti-TNFα therapies appear to be effective and could represent a suitable option in highly refractory MC patients.
- Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
HISTOLOGIC IMPROVEMENT WITH VEDOLIZUMAB VS ADALIMUMAB IN ULCERATIVE COLITIS: RESULTS FROM VARSITY (C2) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2071;
P3
These data support the use of VDZ over ADA in UC. a Adjusted treatment difference and nominal P value: based on the Cochran-Mantel-Haenszel method, stratified by concomitant use of oral corticosteroids (Yes/No) and prior use of anti-TNF therapy (Yes/No); vedolizumab versus adalimumab.
- INDIRECT TREATMENT COMPARISON OF USTEKINUMAB VERSUS OTHER ADVANCED THERAPIES IN MODERATE TO SEVERE ULCERATIVE COLITIS AFTER 1 YEAR (B2) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2047;
Results of the 1-year ITC indicate a higher likelihood of response and remission on UST in non-biologic failure population versus comparators, especially versus anti-TNFs. In biologic failure patients, results were more uncertain due to smaller sample sizes and data limitations, though a higher likelihood of response to UST versus most comparators was observed.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
ASSESSMENT OF THE NEED FOR THE FIRST INTESTINAL RESECTION IN PATIENTS WITH CROHN'S DISEASE FOLLOWING DIAGNOSIS: A SINGLE-CENTRE COHORT STUDY IN JAPAN (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1695;
This study showed a significant reduction in the rates of initial intestinal resection in patients with CD diagnosed during 2002-2012 than those diagnosed during 1990-2001. It is assumed that a decrease in patients with stricturing and penetrating disease and an increase in IM and anti-TNF agents use may have contributed to the decrease in the intestinal resection rate beyond 2001.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
SPACING THE ADMINISTRATION INTERVAL OF ANTI-TNF AGENTS: A VALID STRATEGY FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE? (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1690;
Aims & Aim : To describe the clinical outcomes of IBD patients treated with anti-TNF agents by means of a spacing schedule (administration interval greater than 8 weeks for infliximab or 2 weeks for adalimumab). Anti-TNF administration at longer intervals than those provided in the data sheet of the drug can be a convenient and cheaper alternative, particularly effective in patients in whom anti-TNF treatment was early initiated (within 5 years from disease diagnosis) and once deep remission has been achieved.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
SAFETY AND EFFECTIVENESS OF GRANULOCYTE AND MONOCYTE ADSORPTIVE APHERESIS IN ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A MULTICENTRE COHORT STUDY (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1686;
A rather low incidence rate of AEs (3.9%) was identified in elderly IBD patients treated with GMA, and not displaying any special situation, while the incidence of AEs was significantly higher in patients with one or more special situation (16%), which could be attributed to anaemia or multiple IMs. Remission and response was achieved by GMA in approximately 50% and 70% of the elderly UC patients, respectively.
- EFFICACY AND SAFETY OF USTEKINUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN´S DISEASE: A REAL WORLD STUDY IN BRAZIL (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1684;
Both UST induction and maintenance regimens until week 56 were overall well tolerated. These results support a favorable safety and efficacy profile.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
META-ANALYSIS: DEEP REMISSION IN IBD WITH ANTI-TNF AGENTS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1676;
Anti-TNF agents achieved deep remission in IBD in 37.7% of patients, with rates similar between adalimumab and infliximab. Unfortunately, a lack of available trials precludes the comparison of IFX and ADA in UC and CD.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, azathioprine orodispersible / Generic Mfg.
OPTIMIZATION OF DOSES OF THIOPURINIC DRUGS (AZATIOPRINE AND MERCAPTOPURINE) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDER TREATMENT COMBINED WITH ANTI-TNF ALPHA (INFLIXIMAB/ADALIMUMAB) (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1675;
Consistent with the findings of other studies, there are no differences in the pharmacokinetic characteristics or in the responses of patients with the biologic treatment combined with thiopurine a standard dose with respect to the group with low dose (< 2 mg/kg). The use of a lower dose of Azathioprine can provide a better tolerance of the drug, a better safety profile, and lower economic cost.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
HIGH PLATELET COUNT PREDICTS A RAPID RESPONSE TO ADALIMUMAB AND A FAVOURABLE SHORT-TERM OUTCOME IN PATIENTS WITH ULCERATIVE COLITIS: A MULTI-CENTRE RETROSPECTIVE COHORT STUDY (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1672;
Up to an 80% of the rapid responders also achieved remission at 12 weeks. The rate of rapid response was significantly higher in patients with platelet count ≥312 × 109 /L.
- THERAPEUTIC INTENSIFICATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - A COMPARISON OF DIFFERENT BIOLOGIC THERAPIES (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1670;
This was a retrospective cohort single center study including patients under maintenance therapy with Infliximab (IFX), Adalimumab (ADA), Golimumab (GLB) or Vedolizumab (VDZ). Therapeutic intensification is more frequent and occurs earlier in patients with UC, regardless of the treatment used.
- Humira (adalimumab) / Eisai, AbbVie
ASSESSMENT OF PATIENTS' PREFERENCE FOR A NEW AUTO-INJECTION PEN COMPARED WITH THE PREFILLED SYRINGE FOR SELF-ADMINISTRATION OF ADALIMUMAB IN PATIENTS WITH CROHN'S DISEASE: A PROSPECTIVE COHORT STUDY (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1657;
Further, approximately 70% of patients answered that the new pen was generally better than the syringe at the first self-injection. In addition, the proportion of patients who preferred the new pen was higher at the seventh self-injection than at the first self-injection.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
LONG-TERM OUTCOMES OF INFLIXIMAB THERAPY FOR PATIENTS WITH CROHN'S DISEASE AT DIFFERENT TIMES OF INITIATION OF INFLIXIMAB ADMINISTRATION: A SINGLE-CENTRE COHORT STUDY IN JAPAN (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1656;
The rates of dose escalation of infliximab and intestinal resection of patients with Crohn's disease who were administered infliximab after 2011 were lower than those of patients who were administered infliximab before 2010. Early induction of infliximab and a combined therapy with infliximab and immunomodulators in the 2011-2017 period may have contributed to the reduction in the rates of dose escalation of infliximab and intestinal resection.
- A MULTICENTRIC STUDY ON THE EFFECTIVENESS OF ANTI-TNF AGENTS IN SYMPTOMATIC STRICTURING CROHN'S DISEASE (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1650;
One hundred-forty one patients (54%) received infliximab and 121 (46%) adalimumab. Anti-TNF agents are effective in approximately 20% of patients with Crohn's disease complicated with symptomatic strictures, avoiding surgery in a relatively high proportion of cases.
- LIVING WITH ULCERATIVE COLITIS IN GERMANY: EXPLORING CONCOMITANT STEROID AND IMMUNOSUPPRESSANT USE AMONG PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1643;
Over a quarter of IM users were newly initiated on IM treatment following biologic initiation. These data suggest that control with biologic monotherapy is often insufficient treatment, highlighting the need for further advanced treatment options for this patient population.
- LIVING WITH ULCERATIVE COLITIS IN GERMANY: ESTIMATING THE FREQUENCY AND EXTENT OF DOSE ESCALATIONS AMONG PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1642;
The prevalence and timing of dose escalations differed significantly between biologic therapies, with the largest proportion of dose escalations observed for ADA. These data suggest that many patients may require dose escalations to achieve and maintain remission when being treated with current biologic therapies.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
PRELIMINARY ANALYSIS OF UTILISATION AND CLINICAL RESULTS FROM THE NHS SCOTLAND THERAPEUTIC DRUG MONITORING SERVICE FOR BIOLOGIC MEDICINES (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1640;
It is estimated that > 50% of individuals treated with IFX or ADL have been tested at least once in the first year. DL results were found to be similar to previously published data, as were rates of antibody positivity.
- SUBOPTIMAL ADHERENCE TO VACCINATION IN PREGNANT PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON BIOLOGICS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1632;
These results will serve as a starting point for establishing determinants of suboptimal adherence within the studied population. Ultimately, targeted education programs can be developed.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
OPPORTUNISTIC INFECTION IN PATIENTS WITH INFLAMMATORY DISEASE USING BIOLOGICAL THERAPY. (PROSPECTIVE STUDY) (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1623;
Patients undergoing biological therapy are more susceptible to becoming infected with clostridium, and not only those hospitalised or receiving antibiotics. This study points to the importance of clostridium research in this specific group of patients.
- Humira (adalimumab) / Eisai, AbbVie
USEFULNESS OF SERUM LEUCINE-RICH ALPHA-2-GLYCOPROTEIN (LRG) FOR MONITORING THE EFFICACY OF ADALIMUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE (PLANET STUDY) (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1618;
LRG is a novel serum biomarker for CD, which specially represents endoscopic activity of the disease. LRG may be superior to CRP and fCP for monitoring CD under adalimumab treatment.
- Humira (adalimumab) / Eisai, AbbVie
USEFULNESS OF LEUCINE-RICH ALPHA-2-GLYCOPROTEIN (LRG) TO MONITOR THE EFFICACY OF ADALIMUMAB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS (PLANET STUDY) (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1613;
LRG may be superior to CRP and fCP for monitoring CD under adalimumab treatment. LRG is a novel serum biomarker which can reflect disease activity possibly better than CRP and fCP in UC patients with adalimumab treatment.
- Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
INTERLEUKINS LEVELS: ARE WE ON THE ROAD TO TAILORED THERAPY IN INFLAMMATORY BOWEL DISEASE? (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1605;
IFN-g and TGF-b1 may be useful to identify AZA responders and IL8 and IL6 levels could be good predictors of response to both biological and immunosuppressive drugs. Our study is a first step for tailored therapy in IBD patients.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
INADEQUATE FERTILITY AND PREGNANCY KNOWLEDGE IS RELATED TO VOLUNTARY CHILDLESSNESS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN SERBIA-RESULTS FROM TWO REFERRAL CENTERS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1597;
The CCPKnow score is extremely low in the examined population and is not related to the decision to have children after IBD diagnosis. Patients who had children after IBD was diagnosed were significantly younger at diagnosis and had more children than those who remained childless after IBD was diagnosed.
- Humira (adalimumab) / Eisai, AbbVie
TIME TRENDS OF CROHN´S DISEASE IN CATALONIA FROM 2011 TO 2017. INCREASING USE OF BIOLOGICS CORRELATES WITH A DECREASE IN SURGICAL REQUIREMENTS. A POPULATION-BASED STUDY IN CATALONIA (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1593;
Use of biological drugs increased from 15.0% to 18.7% from 2011 to 2017. During the same periods we observed an improvement in the outcomes of CD patients.
- EFFECTS OF MATRIX METALLOPROTEINASE (MMP)-7, MMP-13 AND CATHEPSIN G ON THE INTEGRITY AND FUNCTION OF ANTI-TUMOUR NECROSIS FACTOR (TNF)-α AND ANTI-INTEGRIN BIOLOGIC AGENTS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1587;
Despite being known to cleave immunoglobulins,2 MMP-7 and MMP-13 do not appear to impair the integrity and function of Infliximab and Adalimumab. In keeping with our previous findings, Etanercept appears to be highly susceptible to the action of proteases.
- Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
HIGH SEROCONVERSION RATE TO TRIVALENT INFLUENZA VACCINE DURING USTEKINUMAB TREATMENT IN CROHN'S DISEASE: RESULTS FROM A PROSPECTIVE COHORT STUDY (A2) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1205;
Seroconversion rate to the seasonal trivalent influenza vaccination during ustekinumab treatment in CD patients is high, in contrast to the reduced rate observed for adalimumab. Patients treated with ustekinumab can be effectively vaccinated with the trivalent influenza vaccine.
- REAL-WORLD SAFETY OF VEDOLIZUMAB AND ANTI-TNF THERAPIES IN BIOLOGIC-NAÏVE ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY (A2) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1202;
Bio-naïve pts treated with VDZ had a significantly lower likelihood of experiencing SAEs and SIs, including GI infections, than those treated with anti-TNF therapies. These data support a favourable safety profile of VDZ versus anti-TNF in bio-naïve inflammatory bowel disease pts in real-world clinical practice.
- Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Treatment aims of therapeutic drug monitoring (C3) - Aug 18, 2019 - Abstract #UEGW2019UEGW_24;
In the recent pediatric PAILOT trial, a proactive dose-adjustment of adalimumab based on TDM and inflammatory markers was superior to conventional therapy for improving long-term outcomes of CD patients. More trials on 'proactive TDM' are eagerly awaited.
- || Humira (adalimumab) / Eisai, AbbVie
If you're filming a commercial and the guy is supposed to be painting a wall, it's a lot more realistic if the paintbrush has paint on it. #humira @abbvie (Twitter) - Aug 18, 2019
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Successful Treatment of Refractory Juvenile Dermatomyositis With Adalimumab. (Pubmed Central) - Aug 17, 2019
More trials on 'proactive TDM' are eagerly awaited. No abstract available
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Prolonged Persistence of Adalimumab Transferred From Mother to Infant During Pregnancy. (Pubmed Central) - Aug 17, 2019
No abstract available No abstract available
- | Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Journal: Chronic granulomatous disease as a rare differential diagnosis of inflammatory bowel disease (Pubmed Central) - Aug 17, 2019
In light of recent literature, this case report shows that chronic granulomatous disease should be considered as a differential diagnosis to therapy refractory IBD. This is the case, especially in young patients, when recurrent bacterial lesions caused by intestine-atypical pathogens appear.
- | Retrospective data, Review, Journal, HEOR: Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. (Pubmed Central) - Aug 16, 2019
Compared with vedolizumab, tofacitinib was associated with a similar number of QALYs, at a lower cost. Tofacitinib is an efficacious treatment for moderately to severely active ulcerative colitis and is likely to be a cost-effective use of NHS resources.
- ||| upadacitinib (ABT-494) / AbbVie, Humira (adalimumab) / Eisai, AbbVie
Clinical: Lucky timing! Just put up an episode on SELECT-COMPARE (upadacitinib vs. adalimumab vs. placebo). https://t.co/yJyG1nlVvF Why the VTE warning? Have not seen evidence of that in the trials yet. Assuming concerns about class effect? (Twitter) - Aug 16, 2019
- || Humira (adalimumab) / Eisai, AbbVie
AbbVie scores blockbuster approval for RA med Rinvoq, its crucial Humira followup https://t.co/91ErPRLGlB (Twitter) - Aug 16, 2019
- ||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
@IBD_Afzali - Perhaps just remember the magic number 10 for Adalimumab and Infliximab as good therapeutic level #ibdschool #acgregional19 (Twitter) - Aug 16, 2019
- ||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Reimbursement: In addition to my comments above about why Humira won’t work after primary non-response to infliximab, Entocort is not approved to treat #UC and there are not data for it in this situation. If you can, call your state insurance commissioner. (Twitter) - Aug 15, 2019
- | Humira (adalimumab) / Eisai, AbbVie
Biomarker, Clinical, Journal: Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. (Pubmed Central) - Aug 15, 2019
P4
Glycoprotein acetylation improvement may partially explain the beneficial effects of adalimumab seen in observational studies. Larger studies with more detailed phenotyping of vascular disease should assess the comparative differences in the effects of adalimumab and phototherapy seen in our study.
- || Xeljanz (tofacitinib) / Pfizer, Humira (adalimumab) / Eisai, AbbVie
UC pt here experiencing same: PNR to IFX, no response to vedo, BCBS will not approve #Xeljanz without 12-week trial of Humira first. Also will not approve #Uceris w/o failing Entocort within last 90 days. Afraid I will lose colon before getting meds that work. (Twitter) - Aug 15, 2019
- | Humira (adalimumab) / Eisai, AbbVie, Cosentyx (secukinumab) / Novartis
Journal: Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. (Pubmed Central) - Aug 15, 2019
Larger studies with more detailed phenotyping of vascular disease should assess the comparative differences in the effects of adalimumab and phototherapy seen in our study. No abstract available
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Early Predictors of the Long-term Response to Therapy in Patients With Crohn Disease Derived From a Time-Intensity Curve Analysis After Microbubble Contrast Agent Injection. (Pubmed Central) - Aug 15, 2019
No abstract available The analysis of time-intensity curves obtained after microbubble contrast agent injection provides early predictors of the long-term therapeutic outcome in patients with CD.
- | Humira SC (adalimumab/hyaluronidase) / AbbVie, Xeljanz (tofacitinib) / Pfizer, Humira (adalimumab) / Eisai, AbbVie
Journal: Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. (Pubmed Central) - Aug 15, 2019
P3
The analysis of time-intensity curves obtained after microbubble contrast agent injection provides early predictors of the long-term therapeutic outcome in patients with CD. This analysis suggests that disease-specific composite measures are appropriate for evaluating treatment efficacy on multiple disease domains in PsA.